References
- 1. Aldape KD, Ballman K, Furth A, Buckner JC, Giannini C, Burger PC, Scheithauer BW, Jenkins RB, James CD. Immunohistochemical detection of EGFRvIII in high malignancy grade astrocytomas and evaluation of prognostic significance // J Neuropathol Exp Neurol, 2004; 63(7):700 - 707
- 2. Bailey PC, Cushing H. A classification of the tumors of the glioma group on a histogenetic basis with a correlated study of prognosis // Can Med Assoc J, 1926; 16:872
- 3. Beier D, Hau P, Proescholdt M, Lohmeier A, Wischhusen J, Oefner PJ, Aigner L, Brawanski A, Bogdahn U, Beier CP. CD133(+) and CD133() glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles // Cancer Res, 2007; 67(9):4010 - 4015
- 4. Camelo-Piragua S, Jansen M, Ganguly A, Kim JC, Louis DN, Nutt CL. Mutant IDH1-specific immunohistochemistry distinguishes diffuse astrocytoma from astrocytosis // Acta Neuropathol, 2010; 119(4):509 - 511
- 5. Capper D, Mittelbronn M, Meyermann R, Schittenhelm J. Pitfalls in the assessment of MGMT expression and in its correlation with survival in diffuse astrocytomas: proposal of a feasible immunohistochemical approach // Acta Neuropathol, 2008; 115(2):249 - 259
- 6. Christensen K, Schroder HD, Kristensen BW. CD133 identifies perivascular niches in grade II-IV astrocytomas // J Neurooncol, 2008; 90(2):157 -170
- 7. Griguer CE, Oliva CR, Gobin E, Marcorelles P, Benos DJ, Lancaster JR, Gillespie GY. CD133 is a marker of bioenergetic stress in human glioma // PLoS ONE, 2008; 3:11
- 8. Daumas-Duport C, Scheithauer B, O’Fallon J, Kelly P. Grading of astrocytomas. A simple and reproducible method // Cancer, 1988; 62:2152 -2165
- 9. Del Vecchio CA, Li G, Wong AJ. Targeting EGF receptor variant III: tumor-specific peptide vaccination for malignant gliomas // Expert Rev Vaccines, 2012; 11(2):133 - 144
- 10. Fischer I, de la Cruz C, Rivera AL, Aldape K. Utility of chromogenic in situ hybridization (CISH) for detection of EGFR amplification in glioblastoma: comparison with fluorescence in situ hybridization (FISH) // Diagn Mol Pathol, 2008; 17(4):227 - 230
- 11. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, Bromberg JE, Hau P, Mirimanoff RO, Cairncross JG, Janzer RC, Stupp R. MGMT gene silencing and benefit from temozolomide in glioblastoma // N Engl J Med, 2005; 352:997 - 1003
- 12. Kim W, Liau LM. IDH mutations in human glioma // Neurosurg Clin N Am, 2012; 23(3): 471 - 480
- 13. Kleihues P, Ohgaki H. Primary and secondary glioblastomas: from concepts to clinical diagnosis // Neuro Oncol, 1999; 1:44 - 51
- 14. Le Mercier M, Hastir D, Moles Lopez X, de Nève N, Maris C, Trepant AL, Rorive S, Decaestecker C, Salmon I. A simplified approach for the molecular classification of glioblastomas // PLoS ONE, 2012; 7:9
- 15. Liang Y, Diehn M, Watson N, Bollen AW, Aldape KD, Nicholas MK, Lamborn KR, Berger MS, Botstein D, Brown PO, Isral MA. Gene expression profiling reveals molecularly and clinically distinct subtypes of glioblastoma multiforme // Proc Natl Acad Sci U S A, 2005; 102(16): 5814 - 5819
- 16. Liu G, Yuan X, Zeng Z, Tunici P, Ng H, Abdulkadir IR, Lu L, Irvin D, Black KL, Yu JS. Analysis of gene expression and chemoresistance of CD133+ cancer stem cell in glioblastoma // Mol Cancer, 2006; 5:67
- 17. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK. Astrocytic tumors // Bosman FT, Jaffe ES, Lakhani RS, Ohgaki H. WHO classification of tumours of the central nervous system. 3rd edition. Lyon: IARC, 2007; 13 - 52
- 18. Loussouarn D, le Loupp AG, Frenel JS, Leclair F, von Deimling A, Aumont M, Martin S, Campone M, Denis MG. Comparison of immunohistochemistry, DNA sequencing and allele-specific PCR for detection of IDH1 mutations in gliomas // Int J Oncol, 2012; 40(6):2058 - 2062
- 19. Mischel PS, Shai R, Shi T, Horvath S, Lu KV, Choe G, Seligson D, Kremen TJ, Palotie A, Liau LM, Cloughesy TF, Nelson SF. Identification of molecular subtypes of glioblastoma by gene expression profiling // Oncogene, 2003; 22(15):2361 - 2373
- 20. Miyuki U, Mieko S, Oba S, Anamaria AC, Moura RP, Henrique PA, Navarro HC, Begnami M, Rosemberg S, Teixeira MJ, Nagahashi KS. Correlation of MGMT promoter methylation status with gene and protein expression levels in glioblastoma // Clinics (Sao Paulo), 2011; 66(10):1747 - 1755
- 21. Nicholas MK, Lukas RV, Chmura S, Yamini B, Lesniak M, Pytel P. Molecular heterogeneity in glioblastoma: therapeutic opportunities and challenges // Semin Oncol, 2011; 38(2):243 - 253
- 22. Nutt CL, Mani DR, Betensky RA, Tamayo P, Cairncross JG, Ladd C, Pohl U, Hartmann C, McLaughlin ME, Batchelor TT, Black PM, von Deimling A, Pomeroy SL, Golub TR, Louis DN. Gene expression-based classification of malignant gliomas correlates better with survival than histological classification // Cancer Res, 2003; 63(7):1602 - 1607
- 23. Ohgaki H, Kleihues P. Genetic pathways of primary and secondary glioblastoma. Am J Pathol, 2007; 170(5):1445 - 1453
- 24. Pallini R, Ricci-Vitiani L, Banna GL, Signore M, Lombardi D, Todaro M, Stassi G, Martini M, Maira G, Larocca LM, de Maria R. Cancer stem cell analysis and clinical outcome in patients with glioblastoma multiforme // Clin Cancer Res, 2008; 14:8205 -8212
- 25. Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, Mankoo P, Carter H, Siu IM, Gallia GL, Olivi A, McLendon R, Rasheed BA, Keir S, Nikolskaya T, Nikolsky Y, Busam DA, Tekleab H, Diaz LA Jr, Hartigan J, Smith DR, Strausberg RL, Marie SK, Shinjo SM, Yan H, Riggins GJ, Bigner DD, Karchin R, Papadopoulos N, Parmigiani G, Vogelstein B, Velculescu VE, Kinzler KW. An integrated genomic analysis of human glioblastoma multiforme // Science, 2008; 321(5897):1807 -1812
- 26. Pelloski CE, Mahajan A, Maor M, Chang EL, Woo S, Colman H, Yang H, Ledoux A, Blair H, Passe S, Jenkins RB, Aldape KD. YKL-40 expression is associated with poorer response to radiation and shorter overall survival in glioblastoma // Clin Cancer Res, 2005; 11:3326 - 3334
- 27. Perry A, Aldape KD, George DH, Burger PC. Small cell astrocytoma: an aggressive variant that is clinicopathologically and genetically distinct from anaplastic oligodendroglioma // Cancer, 2004; 101:2318 - 2326
- 28. Phillips HS, Kharbanda S, Chen R, Forrest WF, Soriano RH, Wu TD, Misra A, Nigro JM, Colman H, Soroceanu L, Williams PM, Modrusan Z, Feuerstein BG, Aldape K. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis // Cancer Cell, 2006; 9(3):157 - 173
- 29. Preusser M, Charles Janzer R, Felsberg J, Reifenberger G, Hamou MF, Diserens AC, Stupp R, Gorlia T, Marosi C, Heinzl H, Hainfellner JA, Hegi M. Anti-O6-methylguaninemethyltransferase (MGMT) immunohistochemistry in glioblastoma multiforme: observer variability and lack of association with patient survival impede its use as clinical biomarker // Brain Pathol, 2008; 18:520 -532
- 30. Shinojima N, Tada K, Shiraishi S, Kamiryo T, Kochi M, Nakamura H, Makino K, Saya H, Hirano H, Kuratsu J, Oka K, Ishimaru Y, Ushio Y. Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme // Cancer Res, 2003, 63:6962 - 6970
- 31. Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, Henkelman RM, Cusimano MD, Dirks PB. Identification of human brain tumour initiating cells // Nature, 2004; 432(7015):396 - 401
- 32. Soejima H, Zhao W, Mukai T. Epigenetic silencing of the MGMT gene in cancer // Biochem Cell Biol, 2005; 83(4):429 - 437
- 33. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO; European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma // N Engl J Med, 2005; 352:987 - 996
- 34. Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, Miller CR, Ding L, Golub T, Mesirov JP, Alexe G, Lawrence M, O’Kelly M, Tamayo P, Weir BA, Gabriel S, Winckler W, Gupta S, Jakkula L, Feiler HS, Hodgson JG, James CD, Sarkaria JN, Brennan C, Kahn A, Spellman PT, Wilson RK, Speed T, Gray JW, Meyerson M, Getz G, Perou CM, Hayes DN. An integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR and NF1 // Cancer Cell, 2010; 17(1):98 - 110
- 35. Viana-Pereira M, Lopes JM, Little S, Milanezi F, Basto D, Pardal F, Jones C, Reis RM. Analysis of EGFR overexpression, EGFR gene amplification and the EGFRvIII mutation in Portuguese high-grade gliomas // Anticancer Res, 2008; 28(2):913 - 920
- 36. Wei KC, Huang CY, Chen PY, Feng LY, Wu TW, Chen SM, Tsai HC, Lu YJ, Tsang NM, Tseng CK, Pai PC, Shin JW. Evaluation of the prognostic value of CD44 in glioblastoma multiforme // Anticancer Res, 2010; 30(1):253 - 259